Canagliflozin is in clinical development for the treatment of chronic kidney disease in adults with type 2 diabetes mellitus. Diabetes is a condition that causes blood sugar level to become too high. The majority of diabetes cases are type 2 diabetes, where the pancreas does not produce enough insulin or when the cells in the body do not respond properly to insulin. Diabetes is the leading cause of chronic kidney disease and failure in adults. People affected by chronic kidney disease have a reduced life expectancy and lower quality of life, as well as substantially increased risk of cardiovascular disease and adverse health outcomes.
Canagliflozin belongs to a class of antidiabetic drugs called SGLT2 inhibitors that act by encouraging the body to filter out more glucose from the blood and excrete it via the urine. Canagliflozin is already licensed for use in type 2 diabetes mellitus but emerging evidence has also suggested that it offers substantial kidney protection, by slowing the progression of diabetic kidney disease. Canagliflozin will offer patients with type 2 diabetes mellitus who have chronic kidney disease a single treatment option to improve both kidney function alongside blood glucose control.
Treosulfan in addition to fludarabine is in clinical development for paediatric non-malignant disease prior to allogeneic stem cell transplant. Treosulfan is a medicine given to patients before they have a bone marrow transplant from a donor known as ‘allogeneic haematopoietic stem cell transplantation’. It is used as a ‘conditioning’ treatment to clear the patient’s bone marrow and make room for the transplanted bone marrow cells, which can then produce healthy blood cells. Treosulfan is used together with another medicine called fludarabine for the treatment of a variety of disorders that require a bone marrow transplant.